Walgreens partners with Epocrates to highlight drug rebates

Share this article:
Walgreens partners with Epocrates to highlight drug rebates
Walgreens partners with Epocrates to highlight drug rebates

Walgreens is hoping physicians will consider its “Prescription Savings Club” list of over 8,000 brand and generic drugs before deciding which script to write for underinsured or cash-strapped patients. Epocrates will provide point of care access to the list via mobile device starting today.

The Prescription Savings Club includes treatments spanning “every drug category” and “most chronic conditions,” like insulin, statins and antivirals, as well as preventative and lifestyle drugs, in categories like weight management, smoking cessation and family planning, according to a statement on the partnership.

Michael Polzin, a spokesperson for Walgreens, said Epocrates was chosen over other mobile drug reference platforms based on its “breadth of use” among physicians. The Prescription Savings Club, which Walgreens describes as a formulary (although it is not affiliated with any health plan), is meant to provide savings to patients without insurance, or filling scripts only partially covered by a health plan. Drug savings are based on the quantitative purchasing power of Walgreens, said Polzin. Walgreens operates 7,580 drugstores in 50 states, and had revenues of $67 billion in fiscal year 2010, according to a statement.

In an April 2009 survey of its users, 68% of physicians (out of 2,075 surveyed) reported having changed a prescribing decision based on formulary information available via Epocrates, according to Erica Sniad Morgenstern, an Epocrates spokesperson.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...